Autoimmune Hepatitis Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape

Autoimmune Hepatitis Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Autoimmune Hepatitis therapeutics.

Synopsis

• In 2022, there will be more than 36.000 diagnosed incidence cases of Autoimmune Hepatitis across 16 pharmaceutical markets.
• No FDA-approved marketed drugs are available for Autoimmune Hepatitis. However, there are several treatments used off-label to manage Autoimmune Hepatitis.
• Among four innovator molecules in the mid- to late-stage pipeline for Autoimmune Hepatitis, only one molecule is in Phase III and the rest are in Phase II.
• 54% of the clinical trials initiated over the last 10 years for Autoimmune Hepatitis have been conducted in sites across Europe.
• Deals involving licensing agreements and partnerships for Autoimmune Hepatitis assets are the most common types globally.
• Innovative therapies for Autoimmune Hepatitis are expected to enter the market no sooner than 2026.

Scope

GlobalData’s Autoimmune Hepatitis: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Retail or Manufacturer Price of Products
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Autoimmune Hepatitis market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Autoimmune Hepatitis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.